Predicting hepatorenal syndrome in cirrhotic patients using biomarkers
Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients
This study is trying to see if new blood and urine tests can help predict if patients with advanced liver disease will develop kidney problems.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | The University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT02434445 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of novel plasma and urinary biomarkers to predict the development of hepatorenal syndrome in patients with advanced cirrhosis. It focuses on biomarkers such as plasma cystatin C, plasma NGAL, and urinary KIM-1, among others. The study compares biomarker levels in advanced cirrhotic patients who have developed hepatorenal syndrome with those who have not. The goal is to correlate these biomarkers with the occurrence of hepatorenal syndrome to improve predictive capabilities.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with advanced cirrhosis (Child's B or C) who are referred for liver transplantation.
Not a fit: Patients with co-existing renal diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier identification and management of hepatorenal syndrome in cirrhotic patients, potentially improving patient outcomes.
How similar studies have performed: Other studies have explored biomarkers in similar contexts, but the specific combination and predictive capability of these biomarkers in this population is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with advanced cirrhosis (Child's B or C) referred for liver transplantation * Willing to give informed consent Exclusion Criteria: * Patients with co-existing renal diseases
Where this trial is running
Hong Kong
- Queen Mary Hospital, Hong Kong — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Principal investigator: Desmond Yap, MD — The University of Hong Kong
- Study coordinator: Desmond Yap, MD
- Email: desmondy@hku.hk
- Phone: 85222553879
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.